DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

The safety and efficacy of early-stage bi-weekly alendronate to improve bone mineral density and bone turnover in chinese post-menopausal women at risk of osteoporosis.

Author(s): You L, Sheng ZY, Chen JY, Pan L, Chen L

Affiliation(s): Department of Osteoporosis, Shanghai First People's Hospital, Shanghai Jiaotong University, 100 Haining Road, Shanghai 200080, China. youlisky2002@126.com

Publication date & source: 2011, J Int Med Res., 39(1):302-10.

Publication type: Randomized Controlled Trial; Research Support, Non-U.S. Gov't

The efficacy and safety of early, low frequency antiresorptive drug intervention for osteopaenia on bone mineral density (BMD) and bone turnover in Chinese post-menopausal women at risk of developing osteoporosis were investigated. A total of 180 women aged 40 - 70 years were enrolled and equally randomized to receive either 70 mg alendronate once every 2 weeks plus 0.5 mug alfacalcidol daily (treatment group) or alfacalcidol 0.5 mug daily alone (control group) for 12 months. In the treatment group, lumbar spine and total hip BMD at 12 months had increased significantly from baseline and compared with the control group. There were also significant reductions in serum levels of the bone turnover biomarkers, bone-specific alkaline phosphatase and C-terminal telopeptide of type I collagen, compared with the control. No serious adverse events were observed in either group and safety profiles were similar. It was concluded that early intervention with 70 mg alendronate once every 2 weeks was safe, well tolerated and more effective than alfacalcidol alone (control) in increasing BMD and reducing bone turnover, and might prevent serious outcomes, such as fragility fractures, reduce rates of adverse effects and improve patient compliance.

Page last updated: 2011-12-09

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017